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A B S T R A C T
Background: By definition bronchiectasis (BE) means destructed structure of normal bronchus as a consequence
of frequent bacterial infections and inflammation. In many senses, BE is a neglected orphan disease. A recent
pan-European registry study, EMBARC, has been set up in order to better understand its pathophysiology, better
phenotype patients, and to individualize their management.
Aim: To examine the aetiology and co-morbidity of BE in the capital area in Finland.
Methods: Two hundred five patients with BE diagnosis and follow up visits between 2016 and 2017 in Helsinki
University Hospital were invited to participate in the study. Baseline demographics, lung functions, imaging,
microbiological, and therapeutic data, together with co-morbidities were entered into EMBARC database.
Clinical characteristics, aetiologic factors, co-morbidities, and risk factors for extensive BE were explored.
Results: To the study included 95 adult patients and seventy nine percent of the BE patients were women. The
mean age was 69 years (SD ± 13). Asthma was a comorbid condition in 68% of the patients but in 26% it was
estimated to be the cause of BE. Asthma was aetiological factor for BE if it had been diagnosed earlier than BE. As
41% BE were idiopathic, in 11% the disorder was postinfectious and others were associated to rheumatic disease,
Alpha-1-antitrypsin deficiency, IgG deficiency and Kartagener syndrome. The most common co-morbidities in
addition to asthma were cardiovascular disease (30%), gastroesophageal reflux disease (26%), overweight
(22%), diabetes (16%), inactive neoplasia (15%), and immunodeficiency (12%). Extensive BE was found in 68%
of BE patients in whom four or more lobes were affected. Risk factors for extensive BE were asthma (OR 2.7),
asthma as aetiology for BE (OR 4.3), and rhinosinusitis (OR 3.1).
Conclusions: Asthma was associated to BE in 68% and it was estimated as aetiology in every fourth patient.
However, retrospectively, it is difficult to exclude asthma as a background cause in patients with asthma-like
symptoms and respiratory infections. We propose asthma as an aetiology factor for BE if it is diagnosed earlier
than BE. Asthma and rhinosinusitis were predictive for extensive BE.
1. Introduction
Different factors may cause destruction that results in the irrever-
sible enlargement and dysfunction of bronchi. Constant neutrophilic
inflammation leads to excessive sputum production which increases the
risk of recurrent airway infections. Together with chronic cough, these
are the classical symptoms of bronchiectasis (BE).
BE, as an orphan lung disease, has mostly been under-researched
and under-resourced. It is now recognised that BE is placing an in-
creasing burden on healthcare systems around the world and there is an
urgent need for better treatments, better clinical care, and for clinical
and translational research into this condition.
In the United States, the prevalence of BE was estimated at 53 to
566 cases per 100,000 inhabitants in 2005. Prevalence increases with
age and female gender [1].
The prevalence in Finland is little studied and may be under-
estimated. In 1992, the Finnish incidence was estimated at 2.7/100,000
[2].
In an analysis of seven European databases of BE outpatients,
comprising a total of 1285 patients, 15% of the BE cases associated to
chronic obstructive pulmonary disease (COPD), and 3.3% to asthma
[3]. In a large Spanish study, COPD was found in 7.8% of the BE cases,
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and asthma in 5.4% [4].
In a USA registry study, where asthma and COPD were evaluated as
comorbidities to BE, asthma was associated to 29% of BE patients and
COPD to 20% [1]. Of these 1826 patients, 55% had radiographic
findings (any dilated airways, thickened airway walls, or mucoid im-
paction) in more than three lobes. Any spirometric obstruction was
found in 51% of the patients, 39% used inhaled corticosteroids, and
61% inhaled bronchodilators.
This study was performed in collaboration with the European
Multicentre Bronchiectasis Audit and Research Collaboration
(EMBARC). We aimed to analyse aetiology factors for BE in Finland and
risk factors for extensive (multilobar) BE.
2. Materials & methods
This study is a part of larger multicenter pan-European EMBARC
(European Multicenter Bronchiectasis Audit and Research
Collaboration) study that was established in 2012 [5].
2.1. Patients and data collection
The present cross-sectional study focused on characterizing the
population with non-cystic fibrosis BE. Patients were recruited between
08/2016–03/2018 from three different units in Helsinki University
Central Hospital (HUH) catchment area: 1) Helsinki University
Hospital, Heart and Lung Center; 2) Helsinki University Hospital, Skin
and Allergy Hospital; and 3) Hospital of Espoo, pulmonary diseases.
Altogether 205 non-cystic fibrosis BE diagnosed patients were sent a
recruitment letter and 103 patients were willing to take a part (Fig. 1).
Eight patients were excluded for lack of BE diagnosis and 95 were in-
cluded. The inclusion criteria were: 1) Doctor – patient relationship in
HUCH; 2) Over 18 years-of-age; 3) High resolution computed tomo-
graphy (HRCT) diagnosed BE; and 4) Non-cystic fibrosis BE.
The following data were collected from the hospital's database and
medical records: the anamnesis of early respiratory infections and re-
spiratory symptoms; the latest lung function; other lung diseases;
smoking status; comorbidities and bacterial colonisation in the sputum
or bronchoalveolar lavage samples [5,6].
Asthma was considered to be an aetiology factor if it had been di-
agnosed before BE and no other driver was found. Diagnosis of asthma
was based on symptoms and airway reversibility shown either in
spirometry (obstruction and a significant bronchodilator response by
+12% in FEV1 or in FVC), or in PEF recording (+15% bronchodilator
response or +20% day-to-day variability or +20% PEF level increase
by asthma medication), by PEF or FEV1 decrease in exercise test (by
−15%), or by moderate to severe bronchial hyperreactivity in hista-
mine or methacholine challenge [7]. COPD was considered to be an
aetiology driver to BE if it was diagnosed earlier than BE. Connective
tissue diseases (CTD) were considered as an aetiology driver to BE if no
other driver was found. In these cases, CTD had been diagnosed either
in childhood or earlier than BE and CTD was classified severe. Patients
have been reported to have post-infective aetiology of BE if hospitalized
in childhood because of severe lower airway infection or suffered re-
current upper and lower airway infections but if no specific im-
munodeficiency or asthma or COPD had been diagnosed. Aspiration
was reported as an aetiology of BE if there were typical symptoms to-
gether with pharyngeal dysfunction diagnosed by the logopedist ac-
cording to the medical records. The diagnoses of other rare aethiolo-
gies, such as Kartagener syndrome and Williams-Campbell syndrome,
were based on radiological findings. When no specific aetiology factor
was found, was it considered to be idiopathic.
2.2. Radiographic findings
The radiologist examined high resolution computed tomography
(HRCT) and computed tomography images of thorax according to the
BE criteria of Naidich [8]. The number of affected lung lobes and
whether the damage of the bronchus is cylindrical, varicose, or cystic
were recorded. The lingula was considered to be an independent lobe. If
four or more lobes were affected, the disease was considered to be
extensive [1].
2.3. Statistical analyses
Two tailed z-test was used to compare proportions. Independent
samples t-test and Mann-Whitney-U test were used to compare means
and mean ranks respectively. When comparing aetiology factors for BE
in different European populations, statistical significance was corrected
for multiple testing and set at the level of< 0.01. Risk factors for ex-
tensive BE were analysed using logistic regression. In logistic regression
Fig. 1. Flow chart.
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analyses, age, BMI, FEV1 (%), and FVC (%) were considered to be
continuous variables. Statistical analyses were performed with the IBM
SPSS Statistics program, version 22.
Ethical approval
The ethics committee of HUCH approved the study set (ethics
committee registration number: 214/13/03/01/2016).
3. Results
Altogether 74% of the ninety five BE patients were women
(Table 1). The mean age was 69 years (SD ± 13), 66% of the patients
were ex-smokers, and 3% current smokers. Asthma was found in 69% of
the patients but in only 26% it was estimated to be aetiology for BE.
Asthma was considered to be aetiology for BE if asthma diagnosis had
been made before BE diagnosis and if all the other aetiology factors
were excluded and if the radiographic findings did not support infection
for aetiology. The most common co-morbidities in addition to asthma
were cardiovascular disease (30%), gastroesophageal reflux disease
(26%), overweight (22%), diabetes (16%), inactive neoplasia (15%),
immunodeficiency (12%), depression (10%), and anxiety (4%).
BE was considered to be idiopathic in 41% of patients, where no
specific aetiology factor was found. In 11%, the disorder was post-
infectious. In 5%, BE was post-tuberculosis and others were associated
to rheumatic disease, Sjögren syndrome, Alpha-1-antitrypsin defi-
ciency, IgG deficiency, and Kartagener syndrome. In 68% of patients,
BE was found in four or more lobes and in 4% the BE was cystic, which
is considered to be a sign of a more severe disease. In 3.2%, BE was
local, affecting one lobe only, whereas in 15.8% two lobes were af-
fected. In five patients (5%) there had been a clinical suspicion of cystic
fibrosis and these patients had been tested with sweat test or genetic
test, but with negative results. Two of these patients were included in
the asthma group, two in the idiopathic group, and one in the im-
munodeficiency group.
The basal lobes of the lungs were the most often affected. In the
cohort, 88% of the patients had right basal lobe changes and 85% had
left basal lobe changes. The apical lobes were better preserved. Changes
in the left apical lobe occurred in 31% of the patients, whereas changes
in the right apical lobe occurred in 54%. The bronchial changes were
mostly cylindrical and nine (9.4%) patients had cystic changes.
Comparing our findings to previous reports from Europe showed
that asthma was a defined aetiology of BE in Finnish (26%), Greek
(2.5%), EU (3.3%), French (4.0%), and Spanish (5.4%) studies, whereas
none was found in British, Belgian, and Portuguese studies (Table 2)
[3,4,9–13].
Asthma as an aetiology did not differ statistically from other ae-
thiology factors with respect to age, BMI (body mass index), gender,
smoking status, exacerbation frequency, or lung function (Table 3).
Asthma either as a comorbidity or an aethiology (OR 2.65), asthma
as aethiology for BE (OR 4.25), and rhinosinusitis (OR 3.12) statistically
increased the risk for extensive BE (Table 4). However, when studying
the aetiology for extensive BE in non-smokers, idiopathic was the most
common finding (18 patients, 42% of the non-smokers with extensive
BE), followed by asthma (16 patients, 37%) (Table 5). Of the total of 65
patients with asthma, 51 (78.5%) had been tested for ABPA and two
had suffered from ABPA. In 65 patients with asthma, 13 (20%) had
increased specific IgE level for Aspergillus fumigatus, total-IgE levels
were 750–1000 kU/l in one, 300–500 kU/l in two, and three patients
had raised IgG level against Aspergillus fumigatus. The other patients
with increased specific IgE level for A. fumigatus were considered to
have asthma with fungal sensitization.
In the group of asthma as aetiology of BE, there was a mean of 18.5
years between the diagnosis of asthma and BE (Table 6). In three pa-
tients, asthma had been diagnosed in childhood. Further, either diag-
nostic bronchodilator response in spirometry or in PEF recording in
medical records was found in 48% of the patients.
In the total BE cohort, 22 (23%) had experienced Pseudomonas
aeruginosa colonisation of sputum now or earlier. Other reported
sputum colonisations were Achromobacter (n=1), Haemophilus (4),
Serratia (3), M avium (2), M intracellulare (1), Staph aureus (2),
Klebsiella (1), Moraxella (1), Morganella (1), Stenotrophomans (1), and
Enterobacter (1). Moreover, when considering infections and im-
munodeficiencies in the total BE cohort, we found one patient with CVI
(common variable immunodeficiency disease), nine patients with IgG
subclass deficiency, one with selective IgA deficiency, one with T-cell
deficiency with combined deficiencies, and one with secondary im-
munodeficiency.
When studying further the association of BE to connective tissue
diseases (in addition to rheumatic disesase) and inflammatory bowel
disease, we found two patients with polymyalgia rheumatica, one with
relapsing polychondritis, three with Sjögren syndrome, and two with
ulcerative colitis.
4. Discussion
In the Finnish BE study population, with a mean age of 69 years,
26% had aetiology of asthma for BE. In these patients, asthma was
diagnosed before BE. Asthma was found as a comorbidity and
Table 1
Demography, comorbidities and radiology findings of the studied population.
n= 95
Gender, female, n (%) 75 (79)
Age, years, mean (± SD) 69 (13)
BMI, kg/m2, mean (± SD) 26 (5)
FEV1, % predicted (± SD) 87 (24)
FVC, % predicted (± SD) 99 (21)
Current smokers, n (%) 3 (3)
Ex-smokers, n (%) 63 (66)
Chronic sputum production, n (%) 78 (82)
M. Tuberculosis, n (%) 5 (5)
P. Aeruginosa colonisation, n (%) 7 (7)
Exacerbations
Non-hospitalized, median (± SD) 1.7 (1.6)




Gastroesophageal reflux disease 25 (26)
Overweight (BMI > 30) 21 (22)
Diabetes, type 2 15 (16)
Inactive neoplasia 14 (15)




Rheumatoid arthritis 5 (5)
Mb.Sjögren 3 (3)
Inflammatory bowel disease 2 (2)
Primary cilia dyskinesia 1 (1)
HRCT, lobes affected, n (%)
One lobe 3 (3.2)
Two lobes 14 (14.7)
Three lobes 13 (13.7)
Four lobes 25 (26.3)
Five lobes 17 (17.9)
Six lobes 23 (24.2)
Lobes affected, mean (± SD) 4.14 (1.47)
≥4 lobes affected 65 (68.4)
Cystic bronchiectasis, n (%) 9 (9.4)
BMI = Body Mass Index; FEV1=Forced expiratory volume in 1 s; FVC =
Forced vital capacity; COPD = Chronic obstructive pulmonary disease; HRCT
= High resolution computed tomography.
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secondary to BE in 45% of the patients. The common other co-mor-
bidities were cardiovascular diseases (30%) and gastroesophageal re-
flux disease (26%). Radiological cystic BE was found in only 9.4% of the
patients. Compared to other BE cohorts, asthma was found approxi-
mately 5–10 times more often as aetiology in Finland. Likewise, post-
infectious BE was 1.5–5 times more common in other BE cohorts
compared to Finland. Risk factors for extensive BE were asthma, either
as comorbidity or aetiology, and rhinosinusitis.
Asthma was considered significantly more often as aetiology for BE
in Finland (26%) than in Greece (2.5%), France (4.0%), or Spain (5.4%)
(Table 2) [4,9,10]. Exceptionally, in Portugal and in Belgium there
were no asthma-driven cases of BE, although the prevalence of asthma
is almost the same in Europe [12,13]. The worldwide comprehensive
meta-analysis (N=8608) has only 1.4% asthma driven BE [14]. In the
US BE Registry, asthma was found as a comorbidity in 29% of 1826 BE
patients [1]. These divergencies might be explained by differences in
Table 3
Characteristics of the BE patients with asthma as aetiology for BE.
Asthma and BE (n= 25) Other and BE (n= 70) p value
Age, years, median (IQR) 74 (66–79) 71 (62.8–76) 0.1ᵃ
BMI, kg/m2 median (IQR) 28.5 (25.1–30.9) 24.2 (21.5–28.6) <0.01ᵃ
Gender, female, n (%) 20 (80) 55 (78.57) 0.88
Current smoker, n (%) 0 (0) 3 (4.29) 0.29
Ex-smoker, n (%) 8 (32) 21 (30) 0.85
HRCT≥4 lobes affected, n (%) 22 (88) 43 (61.4) 0.03
Cystic bronchiectasis, n (%) 1 (4) 8 (11.43) 0.28
Gastroesophageal reflux disease, n (%) 9 (36) 16 (22.86) 0.20
Exacerbations without hospitalization, mean (IRQ) 1.92 (1.66) 1.64 (1.55) 0.46ᵃ
Exacerbations with hospitalizations, mean (IQR) 1.2 (1.91) 0.53 (1.1) 0.06ᵃ
FEV1, % predicted, mean (± SD) 90.3 (19.9) 86.3 (25.6) 0.50
FVC, % predicted, mean (± SD) 99.1 (18.9) 98.4 (21.7) 0.88
HRCT = High resolution computed tomography; FEV1= Forced expiratory volume in 1 s; FVC = Forced vital capacity.
z-test was used to compare proportions. Independent samples t-test and Mann-Whitney U -test (ᵃ) were used to compare means and mean ranks respectively.
Table 4
Risk factors for multilobe (HRCT≥4 lobes affected) BE.
Logistic Regression (age and gender adj.)
Crude-OR 95% CI for EXP p value OR 95% CI for EXP p value
Age 1.02 0.99–1.06 0.17
Gender 0.82 0.29–2.33 0.71 1.02 0.99–1.06 0.17
BMI 1.02 0.94–1.11 0.69
FEV1 (%) 1.00 0.99–1.02 0.49
FVC (%) 1.01 0.99–1.04 0.28
Ever-smokers 5.25 0.42–66.22 0.20 5.21 0.41–66.06 0.20
Non-smokers 4.30 0.37–50.25 0.25 4.29 0.36–50.68 0.36
Chronic sputum production 2.26 0.74 - 6-61 0.14 2.62 0.86–8.04 0.09
Pseudomonas 3.72 1.01–13.74 0.49
Diabetes, type2 1.02 0.94–1.11 0.69
Asthma 2.68 1.08–6.68 0.03 2.65 1.06–6.67 0.04
Asthma as an aetiology 4.60 1.26–16.87 0.02 4.25 1.15–15.75 0.03
Cardiovascular disease 0.71 0.29–1.78 0.47
Psychiatric disease 4.66 0.56–38.6 0.15 6.07 0.7–52.9 0.10
Nasal Polyps 2.04 0.53–7.84 0.30 3.71 0.85–16.11 0.08
Rhinosinusitis 2.67 0.96–7.42 0.06 3.12 1.1–9.05 0.04
Connective tissue disease 0.91 0.25–3.30 0.89
Inflammatory bowel disease 0.45 0.03–7.50 0.58
Immunodeficiency 2.25 0.46–11.12 0.32
Gastroesophageal reflux disease 0.76 0.29–2.00 0.58
Aspiration 2.42 0.27–21.64 0.43 2.18 0.24–19.76 0.49
BMI = Body Mass Index; FEV1= Forced expiratory volume in 1 s; FVC = Forced vital capacity.
Table 5




Connective tissue disease 2 4.7
Idiopathic 18 41.9
IgG subclass deficiency 1 2.3
PCD 1 2.3
Postinfectious 2 4.7
Rheumatoid arthritis 1 2.3
Tuberculosis 1 2.3
Total 43 100.0
PCD = Primary Cilia Dyskinesia.
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diagnosis of asthma and BE. It seems possible that there are regional
differences in how often the patients with mild asthma symptoms or
seasonal asthma symptoms are diagnosed with asthma. Further, it is
well known that prevalence of asthma varies in different populations,
but it has also been shown to differ in the same population in respect to
time [15–17].
We considered asthma as an aetiology factor to BE if asthma was
diagnosed earlier than BE. However, BE might also be associated to
recurrent respiratory infections in an asthma patient. In severe asthma,
BE increases hospitalization rate with OR 2.09 compared to asthma
without BE [18]. The British Thoracic Society recommends asthma to
be considered as a cause of BE if no other specific cause is found [19].
Similarly, if BE in association with asthma is reported to carry poorer
survival and a greater exacerbation rate than asthma alone then also
asthma in association with BE has been reported to increase sig-
nificantly the BE exacerbation risk (OR 2.6, 95% CI 1.15–5.88) [20].
This is in accordance with our finding of asthma increasing the risk for
extensive BE and exacerbations with hospitalizations (1.2 in BE and
asthma, and 0.53 in BE with other background aetiologies) (Table 4).
Likewise, when COPD was defined aetiology of BE in 1.0% in the
Finnish study; there were 6.5% in Greece, 7.8% Spanish, 12.0%
Belgian, 13.0% French, and 15.0% in EU and none in the British and
Portuguese study [3,4,9–13]. COPD was found in 8.0% of BE patients
and in 1% of BE patients COPD were estimated as aetiology. In those
with COPD only as comorbidity, COPD was mild and there were other
aetiology factors for BE.
Extensive BE is characterized as those with four or more lobes af-
fected. In our study, extensive HRCT findings had 68% of the BE pa-
tients whereas in the USA registry data 48% had extensive radiographic
findings [1]. Further, the right upper lobe was the most involved (57%)
and left upper lobe the least involved (44%), whereas in our study the
right basal lobe was the most often affected (88%) and the left upper
lobe was the least often affected (31%).
Postinfectious aetiology of BE in Finland (11%) was more rare than
elsewhere: Belgium (15%), EU (20%), Greece (25%), Spain (30%), UK
(32%) and France (50%) [3,4,9–12]. These comparisons introduce a
possibility that patients with recurrent airway infections might have
had undiagnosed and untreated asthma. In Turkey, primary ciliary
dysfunction, immunodeficiency, and history of tuberculosis were the
most common background causes for BE in patients under 19 years-of-
age, highlighting different regional genetical and environmental in-
fection factors [21,22]. The radiographic findings support the data in
the medical records regarding infections and tuberculosis being rather
rare in our study population since 3.2% of the study individuals had
only one lobe, and 15.8% two lobes, affected. In addition to 11% of
post-infectious BE, 5% of our study population had experienced tu-
berculosis.
GERD (gastroesophageal reflux disease) has been associated with
BE, asthma, and chronic cough. In the US BE Registry, GERD was found
as comorbidity in 47% of 1826 BE patients [1]. In our study, 26% had
GERD and daily proton pump inhibitor (PPI) use. Diagnosis of GERD
was based on the information in medical records. The BE study protocol
did not include esophageal pH-monitoring. Proton pump inhibitors
(PPI) reduce reflux symptoms and acidity but may not inhibit micro
aspiration. Regardless of reflux symptom relief, PPIs have not been
shown effective for cough or asthma symptoms [23,24]. Fundoplication
as a therapeutic option for GERD has been shown to prevent also as-
piration.
Not only GERD, but also hiatal hernia is associated to BE and
especially to its severity [25]. The presence of hiatal hernia has been
reported to associate with cystic BE, increased number of lobes in-
volved, increased extent of BE, and reduced lung function. In our co-
hort, 6% had been diagnosed aspiration and 2% of those was estimated
as aetiology for BE. The incidence was at the same level compared with
other European studies [4,11–13].
The population was recruited from three Helsinki University
Hospital Pulmonary Clinic at three hospitals and one of the study sites is
the Allergy Department. This may affect the large proportion of asthma
both as aetiology and as comorbidity for BE. It is also possible that
elsewhere mild intermittent or even mild persistent asthma is con-
sidered as recurrent respiratory infections if diagnostic procedures are
different. Because of the reimbursement system of asthma medication,
Finnish asthma patients are diagnosed carefully according to symptoms
and lung function parameters. It is most likely that diagnostic proce-
dure is more thorough in Finland when compared to countries where
asthma is diagnosed according to self-reported symptoms only. In those
patients, who were considered to have asthma as aetiology of BE, de-
tailed information on lung function parameters was not available for all
the patients because of long time interval between asthma and BE di-
agnoses, or because asthma had been diagnosed elsewhere. The time
interval between asthma and BE diagnoses was quite long, a mean of
18.5 years.
All these results remind us of the importance of a systematic ap-
proach also in association to BE. Infectious disease history, screening of
immunodeficiency, rheumatoid arthritis and other connective tissue
diseases, aspiration, obstructive lung diseases (both asthma and COPD)
and ABPA should be evaluated.
5. Conclusions
Asthma is common as aetiology and comorbidity in BE and should
be considered in diagnostics and treatment. BE in association with
asthma has been reported to carry a poorer survival and a greater ex-
acerbation rate than asthma alone. Both obstructive lung diseases were
found in 77% of BE patients. Other co-morbidities were cardiovascular
disease (30%) and gastroesophageal reflux (26%). Asthma either as
aetiology or comorbidity, or rhinosinusitis, increased the risk for ex-
tensive BE.
Table 6
Detailed information on asthma history of those BE patients who were considered to have asthma as aetiology for BE.
N=25 %
Diagnostic bronchodilator response in spirometry 8 33
Diagnostic bronchodilator response or diurnal variation in PEF 7 28
Diagnostic spirometry or PEF recordinga 12 48
Serum total IgE
Serum total IgE elevated 5 20
Serum total IgE normal 9 36
IgE against Aspergillus fumigatus elevated 5 20
Asthma diagnosed in childhood 3 12
Asthma diagnosed years before BE diagnosis, not specified 8 32
Years between asthma and BE diagnosis, mean (SD, min-max) 18.5 (16.1; 1–60)
a For others information of pulmonary function tests performed at the time of asthma diagnosis was not available because of the long time-
interval between asthma and BE diagnoses.
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